Similarly, previous bioinformatic analysis from databases like TCGA, GEO and HPA, supported that high expression of METTL3 was correlated with unfavorable prognosis in various cancers, including gastric cancer [73], colorectal cancer [74], liver cancer [75], prostate cancer [76] and glioma [77]. Here, METTL3 is linked to gastric cancer.